Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 206 versus Opdivo in treatment-naive unresectable or metastatic melanoma
2023-503288-40-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Device-based Delivery → Drug Delivery Systems
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing ABP 206 with Opdivo (2 arms). Primary endpoint: Objective response by week 49. Planned start Aug 2023; status: authorised.
02
Drugs
ABP 206nivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-503288-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503288-40-00.